Sol Gel Technologies Ltd (SLGL) Return on Investment ROI from the fourth quarter of 2025 to fourth quarter of 2024 and for the year 2025, average high and low, overall ranking from Dec 31 2025 to Dec 31 2024 - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Sol gel Technologies Ltd   (NASDAQ: SLGL)


Sol Gel Technologies Ltd's ROI from its fourth quarter of 2025 to the fourth quarter of 2024 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Sol Gel Technologies Ltd's ROI in the fourth quarter of 2025?
Sol gel Technologies Ltd achieved a return on average invested assets (ROI) of 21.46 % in its fourth quarter of 2025, this is above SLGL's average return on investment of -31.22%.
Sol Gel Technologies Ltd invested over the 12 months ending in its fourth quarter of 2025 $26 million

Despite the deterioration in its net income, company has improved ROI compared to the third quarter of 2025.

Within the Healthcare sector 400 other companies had a higher return on investment. While Return on investment, overall ranking has progressed in the Dec 31 2025 quarter, so far to 3626, from total ROI ranking in the third quarter of 2025 at 3631.

Definition and Formula of Return on Investment


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Investment (Dec 31 2025)
IV. Quarter		 0
III. Quarter		 0
II. Quarter		 0
I. Quarter		 (Dec 31 2024)
IV. Quarter
Y / Y Investment Change TTM -22.63 % -23.39 % -24.05 % -28.54 % -25.65 %
Y / Y Net Income Change TTM - - - - -
Investment (TTM) in Millions 24 24 34 21 31
Return On Investment (TTM) 21.46 % 3.78 % 3.56 % -28.96 % -26.05 %
SLGL's Overall Ranking # 3626 # 3631 # # #
Seq. Investment Change TTM -6.25 % -5.88 % -2.53 % -10.03 % -7.17 %
Seq. Net Income Change TTM 432.33 % 0 % - - -
Net Income (TTM) in Millions 5 1 1 -9 -9

SLGL Company Profile >> Back to SLGL Roi Comparisons >> See Annual SLGL Return On Investment



Return On Investment SLGL's Ranking
Within: No.
Industry # 151
Sector # 401
Overall # 3626

Return On Investment Statistics
High Average Low
5.6 %
-31.22 %
-66.82 %
(Dec 31 2021)   (Dec 31 2023)







Financial Statements
Sol Gel Technologies Ltd's IV. Quarter Investments $ 24 Millions SLGL's Balance sheet
Sol Gel Technologies Ltd's IV. Quarter Income $ -6 Millions Quarterly SLGL's Income Statement
SLGL's Income by Division See SLGL's Income by Division


SLGL Annual Return On Investment (Dec 31 2025)
2025		 (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021
Total Investments in Millions 24 31 41 43 57
Y / Y Investment Growth -22.3 % -25.03 % -5.85 % -24.69 % 13.07 %
Net Income in Millions -6 -11 -27 -15 3
Y / Y Net Income Growth - - - - -
Annual Return On Investment -25.8 % -34.62 % -66.82 % -34.46 % 5.6 %


Annual Roi Comment


Definition and Formula of Return on Investment

Other ROI Ratios
Major Pharmaceutical Preparations Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
SLGL's Roi Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for SLGL's Competitors
Subscribers only: Roi for Sol Gel Technologies Ltd's Suppliers
Subscribers only: Return On Investment for SLGL's Customers

Other Ratios
SLGL's Roa SLGL's Inventory Turnover Ratio SLGL's Growth Rates SLGL's Dividend Statistics
SLGL's Profitability Ratios SLGL's Asset Turnover Ratio SLGL's Dividend Growth
SLGL's Roe SLGL's Valuation Ratios SLGL's Financial Strength Ratios SLGL's Dividend Payout Ratio



Companies with similar Return On Investment at Dec 31 2025, within Healthcare Sector ROI
Aurinia Pharmaceuticals Inc   56.37 %
Pulmatrix Inc   53.09 %
Novavax inc   51.88 %
Gsk Plc  51.22 %
Q32 Bio Inc   50.33 %
Idexx Laboratories Inc  48.69 %
Theravance Biopharma inc   46.03 %
Elite Pharmaceuticals Inc   45.80 %
Enlivex Therapeutics Ltd  45.75 %
Galmed Pharmaceuticals Ltd   43.72 %
Abeona Therapeutics Inc   42.25 %
Alpha Tau Medical Ltd  42.04 %
Dariohealth Corp   41.31 %
Acadia Pharmaceuticals Inc   39.64 %
Medinotec Inc   37.45 %
Zevra Therapeutics Inc   36.78 %
Oramed Pharmaceuticals Inc  35.86 %
Ptc Therapeutics inc   35.12 %
Mettler toledo International Inc   34.74 %
Newgenivf Group Limited  32.05 %
Eli Lilly And Company  31.62 %
Indivior Pharmaceuticals Inc   31.00 %
Hutchmed china Limited  30.87 %
Medpace Holdings Inc   30.44 %
Adma Biologics Inc   28.75 %
Carlisle Companies Incorporated  27.24 %
Incyte Corporation  27.08 %
Vaxart Inc   26.63 %
Compugen Ltd  26.32 %
Arrowhead Pharmaceuticals Inc   25.56 %

Date modified: 2026-09-18T13:11:06+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.